Literature DB >> 27086030

Pulmonary hypertension associated with lung diseases and hypoxemia.

Michael J Cuttica1.   

Abstract

Pulmonary hypertension that develops in the setting of underlying lung diseases such as COPD or idiopathic pulmonary fibrosis (IPF) is associated with decreased functional status, worsening hypoxemia and quality of life, and increased mortality. This complication of lung disease is complex in its origin and carries a unique set of diagnostic and therapeutic issues. This review attempts to provide an overview of mechanisms associated with the onset of pulmonary hypertension in COPD and IPF, touches on appropriate evaluation, and reviews the state of knowledge on treating pulmonary hypertension related to underlying lung disease.

Entities:  

Keywords:  COPD; Idiopathic pulmonary fibrosis; Pulmonary hypertension; Treatment

Mesh:

Substances:

Year:  2016        PMID: 27086030     DOI: 10.1007/s10741-016-9551-x

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  100 in total

1.  Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome.

Authors:  M Niijima; H Kimura; H Edo; T Shinozaki; J Kang; S Masuyama; K Tatsumi; T Kuriyama
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

2.  Pulmonary arterial hypertension in patients with sleep apnoea syndrome.

Authors:  E Bady; A Achkar; S Pascal; E Orvoen-Frija; J P Laaban
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

3.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

Review 4.  Pulmonary hypertension in patients with interstitial lung diseases.

Authors:  Jay H Ryu; Michael J Krowka; Patricia A Pellikka; Karen L Swanson; Michael D McGoon
Journal:  Mayo Clin Proc       Date:  2007-03       Impact factor: 7.616

5.  Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.

Authors:  Ganesh Raghu; Rachel Million-Rousseau; Adele Morganti; Loyc Perchenet; Juergen Behr
Journal:  Eur Respir J       Date:  2013-05-16       Impact factor: 16.671

6.  Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Oksana A Shlobin; Shahzad Ahmad; Jim Koch; Scott D Barnett; Niv Ad; Nelson Burton; Kevin Leslie
Journal:  Respiration       Date:  2008-01-24       Impact factor: 3.580

Review 7.  Pulmonary hypertension in interstitial lung disease.

Authors:  J Behr; J H Ryu
Journal:  Eur Respir J       Date:  2008-06       Impact factor: 16.671

8.  Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant.

Authors:  A F Shorr; J L Wainright; C S Cors; C J Lettieri; S D Nathan
Journal:  Eur Respir J       Date:  2007-07-11       Impact factor: 16.671

9.  Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Authors:  Ganesh Raghu; Juergen Behr; Kevin K Brown; Jim J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Steven D Nathan; Athol U Wells; Harold R Collard; Ulrich Costabel; Luca Richeldi; Joao de Andrade; Nasreen Khalil; Lake D Morrison; David J Lederer; Lixin Shao; Xiaoming Li; Patty S Pedersen; A Bruce Montgomery; Jason W Chien; Thomas G O'Riordan
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

10.  A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD.

Authors:  S L Archer; D Mike; J Crow; W Long; E K Weir
Journal:  Chest       Date:  1996-03       Impact factor: 9.410

View more
  1 in total

1.  Protective Effect of Statins on Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients: A Nationwide Retrospective, Matched Cohort Study.

Authors:  Wen-Ting Wu; Chung-Yu Chen
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.